Earnings

Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting.

While the firm’s mind and money continues to gear towards branded and novel drugs, India’s Sun Pharma still maintains a mammoth global generics business, including in the US where Sun saw a healthy leap in sales during its financial second quarter.

After a “remarkable performance” in Q2, Samsung Bioepis enjoyed a calm, but still profitable, third quarter.

Pointing to capacity constraints and an ever-increasing global demand, Aspen has trumpeted its prospects in GLP-1s after striking a deal that could have a significant impact for the firm, both commercially and from a manufacturing standpoint.

Henlius’ results for the first half of 2024 have shown a continued trend in growing sales of its core biological products on the backdrop of the company’s ongoing privatization by parent company Fosun Pharmaceutical.

South Africa’s Adcock Ingram welcomed 11 new product launches during its most recent financial year, as it battled on multiple fronts to maintain and ratchet up capacity at its local manufacturing facilities.

After emerging from bankruptcy and announcing the departure of its CEO, Endo has spoken in optimistic terms of its future prospects, especially its Sterile Injectable operations.

Stada delivered solid growth in the first half of 2024, with complex generics launches and an increasingly prominent biosimilars business enabling two of its three operating divisions to report double-digit sales increases. Meanwhile, management also addressed persistent rumors of a possible sale by Stada’s owners.

Momentum in Europe may see the region’s contribution to Glenmark’s revenues become almost as big as the US business, currently dented by multiple challenges. The firm also outlines how things are poised in India for its biosimilar to Novo Nordisk’s Victoza.

Driven by increased orders, Alvotech is bullish on its US adalimumab biosimilar moving into 2025, as it also look forward to the US launch for its Stelara biosimilar early next year.

After a transformative last fiscal year, Sawai presented its financial first quarter results for its 2025 year, with slight disappointment among analysts due to missed revenue forecasts.

Despite reporting lower revenues in the first half of the year, Formycon continues to see value in its biosimilar projects, with a new candidate to be launched in the second half of 2024.

Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.

Following Towa’s reveal of its medium-term business plan earlier this year, the company has shared its financial first quarter results, which were positively received by select analysts.

Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.

Amneal continues to grow its complex product portfolio, with multiple biosimilars and injectables launches coming in the near future, giving the firm confidence to raise its guidance.

Coherus BioSciences has seen a seismic jump in sales of, and market share for, its US biosimilar pegfilgrastim franchise. The firm is optimistic that the momentum will continue through the year.

Celltrion shrugged off challenges from smaller biosimilars players, calling out “overheated competition from new entrants” as it delivered its results and strategic developments for the second quarter of 2024, including pipeline updates paving the way for trials for its proposed Keytruda and Cosentyx biosimilars.

With a clear focus on complex products, Lupin sets out its launch plans for the year ahead, while battling ongoing litigation over some of its generics.

During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.